Update on central precocious puberty: from etiologies to outcomes

Sena Cantas-Orsdemir, Erica Eugster

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Precocious puberty (PP) is one of the most common reasons for referral to pediatric endocrinologists. Gonadotropin-releasing hormone analogs (GnRHas) are the gold standard for the treatment of central precocious puberty (CPP) and have an impressive record of safety and efficacy. However, ongoing refinements in diagnosis and management continue to lead to important advancements in clinical care. Areas covered: The aim of this review is to cover current considerations and controversies regarding the diagnosis of CPP, as well as new findings in regards to etiology and treatment modalities. Expert opinion: There is emerging evidence of monogenic etiologies of CPP and significant progress in the expansion of newer formulations of GnRHas. Despite these exciting developments, areas of uncertainty in the diagnosis and treatment of CPP remain. While long-term outcomes of patients treated for CPP are encouraging, only short-term follow-up is available with respect to the newer extended release GnRHa preparations, and how they compare with historically used formulations is unknown. A particular shortage of information exists pertaining to CPP in boys and regarding the psychological implications of PP in girls, and more research is needed. Continued investigation will yield new insights into the underlying genetics and optimal treatment strategies for CPP.

Original languageEnglish (US)
Pages (from-to)123-130
Number of pages8
JournalExpert Review of Endocrinology and Metabolism
Volume14
Issue number2
DOIs
StatePublished - Mar 4 2019

Fingerprint

Precocious Puberty
Gonadotropin-Releasing Hormone
Expert Testimony
Therapeutics
Central Precocious Puberty
Uncertainty
Referral and Consultation
Pediatrics
Psychology
Safety
Research
Endocrinologists

Keywords

  • Central precocious puberty
  • etiology
  • genetics
  • outcomes
  • treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Update on central precocious puberty : from etiologies to outcomes. / Cantas-Orsdemir, Sena; Eugster, Erica.

In: Expert Review of Endocrinology and Metabolism, Vol. 14, No. 2, 04.03.2019, p. 123-130.

Research output: Contribution to journalReview article

@article{e68d27fef83e4f1a9ec75c1bc596eefc,
title = "Update on central precocious puberty: from etiologies to outcomes",
abstract = "Introduction: Precocious puberty (PP) is one of the most common reasons for referral to pediatric endocrinologists. Gonadotropin-releasing hormone analogs (GnRHas) are the gold standard for the treatment of central precocious puberty (CPP) and have an impressive record of safety and efficacy. However, ongoing refinements in diagnosis and management continue to lead to important advancements in clinical care. Areas covered: The aim of this review is to cover current considerations and controversies regarding the diagnosis of CPP, as well as new findings in regards to etiology and treatment modalities. Expert opinion: There is emerging evidence of monogenic etiologies of CPP and significant progress in the expansion of newer formulations of GnRHas. Despite these exciting developments, areas of uncertainty in the diagnosis and treatment of CPP remain. While long-term outcomes of patients treated for CPP are encouraging, only short-term follow-up is available with respect to the newer extended release GnRHa preparations, and how they compare with historically used formulations is unknown. A particular shortage of information exists pertaining to CPP in boys and regarding the psychological implications of PP in girls, and more research is needed. Continued investigation will yield new insights into the underlying genetics and optimal treatment strategies for CPP.",
keywords = "Central precocious puberty, etiology, genetics, outcomes, treatment",
author = "Sena Cantas-Orsdemir and Erica Eugster",
year = "2019",
month = "3",
day = "4",
doi = "10.1080/17446651.2019.1575726",
language = "English (US)",
volume = "14",
pages = "123--130",
journal = "Expert Review of Endocrinology and Metabolism",
issn = "1744-6651",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Update on central precocious puberty

T2 - from etiologies to outcomes

AU - Cantas-Orsdemir, Sena

AU - Eugster, Erica

PY - 2019/3/4

Y1 - 2019/3/4

N2 - Introduction: Precocious puberty (PP) is one of the most common reasons for referral to pediatric endocrinologists. Gonadotropin-releasing hormone analogs (GnRHas) are the gold standard for the treatment of central precocious puberty (CPP) and have an impressive record of safety and efficacy. However, ongoing refinements in diagnosis and management continue to lead to important advancements in clinical care. Areas covered: The aim of this review is to cover current considerations and controversies regarding the diagnosis of CPP, as well as new findings in regards to etiology and treatment modalities. Expert opinion: There is emerging evidence of monogenic etiologies of CPP and significant progress in the expansion of newer formulations of GnRHas. Despite these exciting developments, areas of uncertainty in the diagnosis and treatment of CPP remain. While long-term outcomes of patients treated for CPP are encouraging, only short-term follow-up is available with respect to the newer extended release GnRHa preparations, and how they compare with historically used formulations is unknown. A particular shortage of information exists pertaining to CPP in boys and regarding the psychological implications of PP in girls, and more research is needed. Continued investigation will yield new insights into the underlying genetics and optimal treatment strategies for CPP.

AB - Introduction: Precocious puberty (PP) is one of the most common reasons for referral to pediatric endocrinologists. Gonadotropin-releasing hormone analogs (GnRHas) are the gold standard for the treatment of central precocious puberty (CPP) and have an impressive record of safety and efficacy. However, ongoing refinements in diagnosis and management continue to lead to important advancements in clinical care. Areas covered: The aim of this review is to cover current considerations and controversies regarding the diagnosis of CPP, as well as new findings in regards to etiology and treatment modalities. Expert opinion: There is emerging evidence of monogenic etiologies of CPP and significant progress in the expansion of newer formulations of GnRHas. Despite these exciting developments, areas of uncertainty in the diagnosis and treatment of CPP remain. While long-term outcomes of patients treated for CPP are encouraging, only short-term follow-up is available with respect to the newer extended release GnRHa preparations, and how they compare with historically used formulations is unknown. A particular shortage of information exists pertaining to CPP in boys and regarding the psychological implications of PP in girls, and more research is needed. Continued investigation will yield new insights into the underlying genetics and optimal treatment strategies for CPP.

KW - Central precocious puberty

KW - etiology

KW - genetics

KW - outcomes

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85063055496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063055496&partnerID=8YFLogxK

U2 - 10.1080/17446651.2019.1575726

DO - 10.1080/17446651.2019.1575726

M3 - Review article

C2 - 30763521

AN - SCOPUS:85063055496

VL - 14

SP - 123

EP - 130

JO - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

SN - 1744-6651

IS - 2

ER -